Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Characteristics of human Ewing/PNET sarcoma models.

Autor: Teicher BA, Bagley RG, Rouleau C, Kruger A, Ren Y, Kurtzberg L, Teicher, Beverly A, Bagley, Rebecca G, Rouleau, Cecile, Kruger, Ariel, Ren, Yi, Kurtzberg, Leslie

Publikováno v: Annals of Saudi Medicine; Mar2011, Vol. 31 Issue 2, p174-182, 9p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).

Autor: Issa GC; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Aldoss I; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Thirman MJ; Biological Sciences Division, The University of Chicago Medicine, Chicago, IL., DiPersio J; John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO., Arellano M; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Blachly JS; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH., Mannis GN; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Perl A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Dickens DS; University of Iowa Stead Family Children's Hospital, Iowa City, IA., McMahon CM; UCHealth Blood Disorders and Cell Therapies Center, University of Colorado School of Medicine, Aurora, CO., Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, and Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands., Grove CS; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Shami PJ; University of Utah Huntsman Cancer Institute, Salt Lake City, UT., Mantzaris I; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY., Greenwood M; Department of Haematology, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia., Shukla N; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Cuglievan B; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Kovacsovics T; City of Hope Phoenix, Goodyear, AZ., Gu Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Bagley RG; Syndax Pharmaceuticals, Inc, Waltham, MA., Madigan K; Syndax Pharmaceuticals, Inc, Waltham, MA., Chudnovsky Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Nguyen HV; Syndax Pharmaceuticals, Inc, Waltham, MA., McNeer N; Syndax Pharmaceuticals, Inc, Waltham, MA., Stein EM; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 09, pp. JCO2400826. Date of Electronic Publication: 2024 Aug 09.